Decisions 5th September 2017

At the meeting on the 5th September the following decisions were agreed

New Drug Requests


Betamethasone soluble tablets (TLS orange/green)

  • Approved for inclusion onto the formulary for topical management of oral ulceration/oral erosions and inflammation.  TLS depending on indication and whether more general or specialist indication.  TLS green for recurrent  aphthous ulceration and non-specific oral ulceration and inflammation.   TLS Amber one month for oral lichen planus, behcet’s syndrome, pemphigus vulgaris, pemphigus vulgaris, pemphigoid, lupus, oral erythema multiforme, oral-facial granulomatosis.

Isavuconazole (TLS Red)

  • Approved for inclusion onto the formulary for treatment of invasive aspergillosis and mucormycosis in haematology/bone marrow transplant (BMT) patients as per trust guidelines.           

Sucroferric oxyhydroxide (TLS Red)

  • Approved for inclusion onto the formulary for management of hyperphosphataemia in dialysis patients with serum phosphate levels that are not controlled after calcium based binder, sevelamer and/or lanthanum have been tried or in patients intolerant to other agents

Shared Care Protocols/TLS Change in Status


  • SCP updated


  • SCP updated to reflect MHRA alert on osteonecrosis of the jaw


  • For paediatric use
  • Children with neurodevelopmental disorder/disability with intrinsic sleep disorder (difficulty getting to sleep or remaining asleep) who have exhausted all behavioural sleep hygiene options)
  • Not for use in ADHD or Autism or Learning Disabilities

Degarelix (TLS Red to Amber)

  • SCP needs to reviewed and discussed in a future JFG.










Last updated by: Emily Knight on 24-10-2017 15:45